BioSpace News Archive

Orexo´s partner Gesynta Pharma’s drug candidate GS-248 (OX-MPI) granted Orphan Drug Designation in the US by the FDA for the treatment of systemic sclerosis

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, provided an update on the dose escalation portion of the TH1902 Phase 1 clinical safety study.

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report.

Allos Pharma Inc (“Allos”), a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, announces presentation of “Arbaclofen produces clinically meaningful improvements in individuals with Fragile X” at the 18th NFXF International Fragile X Conference, July 14-17th , 2022.

Akili Interactive Labs, Inc., a leading digital medicine company, announced the publication of full data from a randomized, unblinded study conducted by National Jewish Health and the University of Colorado School of Medicine Departments of Neurology, Psychiatry and Rheumatology that evaluated the ability of Akili’s digital therapeutic AKL-T01 to improve cognitive dysfunction in patients diagnosed with Systemic Lupus Erythematosus.

Purple Biotech Ltd. today announced that following the decision by Isaac Israel, former Chief Executive Officer to step down from his CEO role and reduce the scope of his engagement with the Company for personal reasons, effective July 10, 2022, Gil Efron,

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke, announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that pharmacokinetic (PK) data from the single ascending dose portion of a Phase 1 study with its novel, broad-spectrum, orally administered antiviral candidate CC-42344 for the treatment of pandemic and seasonal influenza A support the potential for once-daily dosing.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Susanne Schaffert, Ph.D., to its board of directors.

Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the company’s COVID-19 oral tablet vaccine development program at the International Congress of Mucosal Immunology 2022, which is being held in Seattle July 16 to 20, 2022.